

ASX Announcement

Imugene selected for Oral Presentation at Prestigious ASH Annual Meeting in Florida

Sydney, Australia, 4 November 2025: Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, is pleased to announce that an abstract regarding azer-cel has been selected for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from 6–9 December 2025 in Orlando, Florida.

The ASH Annual Meeting is the world's premier event in malignant and non-malignant haematology, attracting more than 30,000 clinicians, scientists, and industry representatives from over 100 countries. Each year, the meeting highlights the most significant scientific and clinical advances in the field, with oral abstracts representing the highest tier of accepted submissions.

Imugene's abstract, titled "Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T", has been selected for presentation within the session "Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next Generation CAR-T Clinical Trials in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Multiple Myeloma."

The oral presentation will take place on Saturday 6 December 2025, from 2:30pm to 2:45pm US Eastern Time in West Hall D2 of the Orange County Convention Center.

The abstract published overnight includes clinical activity and safety data from the Company's azer-cel (allogeneic CD19 CAR T) program, evaluating the combination with low-dose IL-2 in patients with relapsed or refractory large B-cell lymphoma (LBCL) following prior autologous CAR T-cell therapy. The abstract is linked on Imugene's website at <https://imugene.com/technology/publications/>



Imugene's Managing Director and Chief Executive Officer, Leslie Chong, said: "We are honoured that azer-cel has been selected for oral presentation at ASH, it being the world's leading haematology conference. This puts a spotlight on the growing clinical interest in allogeneic CAR T approaches and represents an exciting opportunity to share new insights from our ongoing study with the global haematology community."

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

info@imugene.com

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts



with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.